Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down to $12.41

Stoke Therapeutics, Inc. (NASDAQ:STOK)’s share price gapped down prior to trading on Monday . The stock had previously closed at $12.41, but opened at $11.80. Stoke Therapeutics shares last traded at $12.12, with a volume of 85,656 shares changing hands.

Analyst Upgrades and Downgrades

STOK has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Thursday, April 4th. TD Cowen upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 26th. Canaccord Genuity Group increased their price objective on Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, March 26th. Wedbush upped their price target on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, April 11th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $19.63.

Stoke Therapeutics Trading Down 4.9 %

The company has a market cap of $615.02 million, a PE ratio of -4.87 and a beta of 0.76. The stock has a 50 day moving average price of $9.43 and a 200 day moving average price of $6.30.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, March 25th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.02. The firm had revenue of $2.80 million for the quarter, compared to analysts’ expectations of $3.70 million. Equities analysts expect that Stoke Therapeutics, Inc. will post -2.28 EPS for the current fiscal year.

Insider Activity at Stoke Therapeutics

In other news, major shareholder Skorpios Trust sold 3,600,000 shares of the stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total value of $41,760,000.00. Following the sale, the insider now directly owns 10,843,681 shares of the company’s stock, valued at $125,786,699.60. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, major shareholder Skorpios Trust sold 3,600,000 shares of the stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the sale, the insider now owns 10,843,681 shares in the company, valued at $125,786,699.60. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $4.80, for a total transaction of $48,000.00. Following the completion of the transaction, the insider now owns 6,981 shares of the company’s stock, valued at $33,508.80. The disclosure for this sale can be found here. Insiders sold a total of 3,632,741 shares of company stock valued at $41,983,115 in the last 90 days. Corporate insiders own 12.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new position in Stoke Therapeutics during the third quarter valued at approximately $53,000. Bank of New York Mellon Corp boosted its stake in shares of Stoke Therapeutics by 2.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 107,254 shares of the company’s stock worth $423,000 after buying an additional 2,926 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Stoke Therapeutics by 9.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company’s stock worth $576,000 after acquiring an additional 12,478 shares during the period. Dorsey & Whitney Trust CO LLC purchased a new stake in Stoke Therapeutics during the third quarter valued at $43,000. Finally, Trexquant Investment LP lifted its holdings in Stoke Therapeutics by 166.9% in the third quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock valued at $503,000 after acquiring an additional 79,785 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.